Pulmonary and Critical Care

For any further information on clinical research studies, or to inquire about enrollment, contact us at osf.clinicalresearch@osfhealthcare.org.

COPD/Emphysema

PULMONX
Lung Function Improvement after Bronchoscopic Lung Volume Reduction with Pulmonx Endobronchial Valves used in Treatment of Emphysema (LIBERATE Study).

PNEUMRX
CLN0009 PneumRx RePneu Lung Volume Reduction Coil (RePneu LVRC) System. Lung Volume Reduction coil for treatment in patients with Emphysema (RENEW) study.

SPIRATION
IBV Valve System Humanitarian Device for use in the Control of Air Leaks

PNEUMRX Crossover
CLN0016 PneumRx RePneu Lung Volume Reduction Coil (RePneu LVRC) System,   LVRC IDE Crossover Study—(crossover from IDE Trial CLN0009, Lung Volume Reduction Coil Treatment in Patients with Emphysema (RENEW) Study, IDE G110066).

Cystic Fibrosis

VX12-809-105
A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment with Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F598del-CFTR Mutation.

PHARMAXIS
Pharmaxis DPM-CF-303: Long Term Administration of Inhaled Mannitol in Cystic Fibrosis—A Safety and Efficacy Trial in Adult Cystic Fibrosis Subjects.

Idiopathic Pulmonary Fibrosis

Intermune
A randomized, double-blind, placebo-controlled, Phase 3 study of the efficacy and safety of Pirfenidone in patients with Idiopathic Pulmonary Fibrosis

Intermune
An open-label extension study of the long-term safety of Pirfenidone in patients with Idiopathic Pulmonary Fibrosis

Interstitial Lung Disease

Veracyte (BRAVE-1)
Bronchial sample collection for a novel genomic test

Veracyte (BRAVE-2)
Bronchial Sample Collection for a Novel Genomic Test

Pulmonary Disease/Critical Care Medicine

AMGEN (Asthma Study)
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Brodalumab in Subjects With Inadequately Controlled Asthma and High Bronchodilator Reversibility.

GSK NAI114373
A Phase III international, randomized, double-blind, double-dummy study to evaluate the efficacy and safety of 300 mg or 600 mg of intravenous zanamivir twice daily compared to 75 mg of oral oseltamivir twice daily in the treatment of hospitalized adults and adolescents with influenza